Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study

References

• Marathe PH, Gao HX, Close KL. American Diabetes Association standards of medical care in diabetes 2017. J Diabetes 2017;9:320–4.
   PubMed Web of Science ®Google Scholar
• Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47–54.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. J Am Med Assoc 2000;284:472–7.
   PubMed Web of Science ®Google Scholar
• Tankova T, Koev D, Dakovska L, Kirilov G. Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract 2002;56:578–81.
   PubMed Web of Science ®Google Scholar
• Moreira PI. Metformin in the diabetic brain: friend or foe? Ann Transl Med 2014;2:54.
   PubMedGoogle Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65.
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–5.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766–77.
   PubMed Web of Science ®Google Scholar
• Koh SJ, Kim JM, Kim IK, Ko SH, Kim JS. Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. J Gastroenterol Hepatol 2014;29:502–10.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Lee SH, Yang E-J, Kim E-K, Kim J-K, Shin D-Y, et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/Treg balance. PLoS One 2015;10:e0135858.
   PubMed Web of Science ®Google Scholar
• Nath N, Khan M, Paintlia MK, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immun 2009;182:8005–14.
   PubMed Web of Science ®Google Scholar
• Kang KY, Kim YK, Yi H, Kim J, Jung HR, Kim IJ, et al. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. Int Immunopharmacol 2013;16:85–92.
   PubMed Web of Science ®Google Scholar
• Son HJ, Lee J, Lee SY, Kim EK, Park MJ, Kim KW, et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm 2014;2014:973986.
   PubMed Web of Science ®Google Scholar
• Yan H, Zhou H-F, Hu Y, Pham CT. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. J Rheum Dis Treat 2015;1:5.
   PubMedGoogle Scholar
• Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based case-control study. J Am Acad Dermatol 2008;58:421–9.
   PubMed Web of Science ®Google Scholar
• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903–11.
   PubMed Web of Science ®Google Scholar
• Israel Central Bureau of Statistics. Healthfunds membership 2015. Jerusalem: Israel Central Bureau of Statistics, 2015.
   Google Scholar
• Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169:260–8.
   PubMed Web of Science ®Google Scholar
• Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence (http://ep.yimg.com/ty/cdn/epill/pdcmpr.pdf). Accessed 3 December 2019.
   Google Scholar
• Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836–41.
   PubMed Web of Science ®Google Scholar
• Central Bureau of Statistics (Israel). Israel Population and Housing Census 2008 (http://ghdx.healthdata.org/record/israel-population-and-housing-census-2008). Accessed 3 December 2019.
   Google Scholar
• Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 2003;18:1143–6.
   PubMed Web of Science ®Google Scholar
• Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010;7:e1000336.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187–202. (http://www.biecek.pl/statystykaMedyczna/cox.pdf). Accessed 3 December 2019.
   Google Scholar
• Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006;47:1183–8.
   PubMed Web of Science ®Google Scholar
• Park MH, Hong JT. Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells 2016;5:15.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
   PubMed Web of Science ®Google Scholar
• Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets 2015;15:196–205.
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 2017;23:850–8.
   PubMed Web of Science ®Google Scholar
• de la Cuesta-zuluaga J, Mueller NT, Corrales-Agudelo V, Velasquez-Mejia EP, Carmona JA, Abad JM, et al. Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 2017;40:54–62.
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528:262–6.
   PubMed Web of Science ®Google Scholar
• Rajaei E, Haybar H, Mowla K, Zayeri ZD. Metformin one in a million efficient medicines for rheumatoid arthritis complications: inflammation, osteoblastogenesis, cardiovascular disease, malignancies. Curr Rheumatol Rev 2019;15:116–22.
   PubMed Web of Science ®Google Scholar
• Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 2016;7:40767–80.
   PubMed Web of Science ®Google Scholar
• Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 2017;60:1639–47.
   PubMed Web of Science ®Google Scholar
• Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2:778–90.
   PubMed Web of Science ®Google Scholar
• Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 2015;16:77–87.
   PubMed Web of Science ®Google Scholar
• Zhao D, Long XD, Lu TF, Wang T, Zhang WW, Liu YX, et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer 2015;136:2556–65.
   PubMed Web of Science ®Google Scholar
• Lu MC, Yan ST, Yin WY, Koo M, Lai NS. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study. PLoS One 2014;9:e101528.
   PubMed Web of Science ®Google Scholar
• Tentolouris A, Thanopoulou A, Tentolouris N, Eleftheriadou I, Voulgari C, Andrianakos A, et al. Low prevalence of rheumatoid arthritis among patients with pre-existing type 2 diabetes mellitus. Ann Trans Med 2018;6:399.
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008;67:769–74.
   PubMed Web of Science ®Google Scholar
• Lu B, Hiraki LT, Sparks JA, Malspeis S, Chen CY, Awosogba JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 2014;73:1914–22.
   PubMed Web of Science ®Google Scholar
• Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis 2015;74:1968–75.
   PubMed Web of Science ®Google Scholar
• Seong JM, Yee J, Gwak HS. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Br J Clin Pharmacol 2019;85:1719–27.
   PubMed Web of Science ®Google Scholar
• Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011;305:480–6.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Yelin E, Katz JN, Lu B, Shaykevich T, Ayanian JZ. Treatment of rheumatoid arthritis in the medicare current beneficiary survey. Arthritis Res Ther 2013;15:R43.
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010;69:70–81.
   PubMed Web of Science ®Google Scholar
• Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 2017;17:60–75.
   PubMed Web of Science ®Google Scholar